RU2005100777A - Моноклональное антитело рам4 и его применение для диагностики и лечения рака поджелудочной железы - Google Patents

Моноклональное антитело рам4 и его применение для диагностики и лечения рака поджелудочной железы Download PDF

Info

Publication number
RU2005100777A
RU2005100777A RU2005100777/13A RU2005100777A RU2005100777A RU 2005100777 A RU2005100777 A RU 2005100777A RU 2005100777/13 A RU2005100777/13 A RU 2005100777/13A RU 2005100777 A RU2005100777 A RU 2005100777A RU 2005100777 A RU2005100777 A RU 2005100777A
Authority
RU
Russia
Prior art keywords
fragment
antibody
diagnostic
pam4
conjugate
Prior art date
Application number
RU2005100777/13A
Other languages
English (en)
Russian (ru)
Inventor
Дэвид В. ГОЛД (US)
Дэвид В. ГОЛД
Дэвид М. ГОЛДЕНБЕРГ (US)
Дэвид М. ГОЛДЕНБЕРГ
Ханс ХАНСЕН (US)
Ханс ХАНСЕН
Original Assignee
Иммуномедикс, Инк. (Us)
Иммуномедикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Иммуномедикс, Инк. (Us), Иммуномедикс, Инк. filed Critical Иммуномедикс, Инк. (Us)
Publication of RU2005100777A publication Critical patent/RU2005100777A/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1057—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from liver or pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
RU2005100777/13A 2002-06-14 2003-06-16 Моноклональное антитело рам4 и его применение для диагностики и лечения рака поджелудочной железы RU2005100777A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38831302P 2002-06-14 2002-06-14
US60/388,313 2002-06-14

Publications (1)

Publication Number Publication Date
RU2005100777A true RU2005100777A (ru) 2005-08-27

Family

ID=29736455

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2005100777/13A RU2005100777A (ru) 2002-06-14 2003-06-16 Моноклональное антитело рам4 и его применение для диагностики и лечения рака поджелудочной железы

Country Status (8)

Country Link
US (1) US7238786B2 (https=)
EP (1) EP1521775B1 (https=)
JP (1) JP5110768B2 (https=)
KR (1) KR101228124B1 (https=)
AU (1) AU2003250367A1 (https=)
CA (1) CA2489469C (https=)
RU (1) RU2005100777A (https=)
WO (1) WO2003106497A1 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2432399C2 (ru) * 2006-06-14 2011-10-27 Эл Джи Лайф Сайенсиз Лтд. Семейство генов (lbfl313), ассоциированных с злокачественным ростом поджелудочной железы
RU2445319C2 (ru) * 2005-11-24 2012-03-20 Ганимед Фармасьютикалз Аг Моноклональные антитела к клаудину-18 для лечения рака
RU2571923C2 (ru) * 2007-05-29 2015-12-27 Ганимед Фармасьютикалз Аг Моноклональные антитела против клаудина-18 для лечения рака

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8038994B2 (en) * 1996-05-15 2011-10-18 Quest Pharmatech Inc. Combination therapy for treating disease
US7591994B2 (en) 2002-12-13 2009-09-22 Immunomedics, Inc. Camptothecin-binding moiety conjugates
US8658773B2 (en) 2011-05-02 2014-02-25 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
US20050260208A1 (en) * 2002-04-11 2005-11-24 Altarex Medical Corp. Binding agents and their use in targeting tumor cells
US7172751B2 (en) * 2003-06-13 2007-02-06 Immunomedics, Inc. D-amino acid peptides
ATE437657T1 (de) * 2004-03-02 2009-08-15 Cellectar Inc Phospholipid-analoga für die behandlung von krebs
WO2006081553A2 (en) * 2005-01-28 2006-08-03 Ramot At Tel Aviv University, Ltd. ANTI-MUC1 α/ß ANTIBODIES
JP2006248978A (ja) * 2005-03-10 2006-09-21 Mebiopharm Co Ltd 新規なリポソーム製剤
JP3989936B2 (ja) * 2005-04-07 2007-10-10 進 須永 抗腫瘍剤及び新規ｄｎアーゼ
WO2007114861A2 (en) * 2005-11-28 2007-10-11 Zymogenetics, Inc. Il-21 receptor antagonists
WO2007127813A2 (en) * 2006-04-25 2007-11-08 Drexel University Modulation of signal transduction by site specific ultrasound agent delivery of transmembrane acting compounds
WO2008091643A2 (en) * 2007-01-23 2008-07-31 Altarex Medical Corp. In vitro culture system to evaluate synergy in targeting immune suppressive pathways concurrent to immunotherapy
EP2604279A1 (en) 2008-03-27 2013-06-19 ZymoGenetics, Inc. Compositions and methods for inhibiting PDGFRBETA and VEGF-A
US20160095939A1 (en) 2014-10-07 2016-04-07 Immunomedics, Inc. Neoadjuvant use of antibody-drug conjugates
ES3000111T3 (en) 2009-02-13 2025-02-27 Immunomedics Inc Intermediates for preparing conjugates with an intracellularly-cleavable linkage
ES2978177T3 (es) 2009-12-02 2024-09-06 Immunomedics Inc Combinación de radio inmunoterapia y conjugados anticuerpo-fármaco para mejorar la terapia contra el cáncer
CA2850572A1 (en) * 2011-10-20 2013-04-25 Esbatech, A Novartis Company Llc Stable multiple antigen-binding antibody
WO2013082299A1 (en) 2011-11-29 2013-06-06 Als Therapy Development Institute Targeting of t-lymphocytes to treat amyotrophic lateral sclerosis
CN104379169A (zh) 2012-08-14 2015-02-25 Ibc药品公司 用于治疗疾病的t-细胞重定向双特异性抗体
WO2017004144A1 (en) 2015-07-01 2017-01-05 Immunomedics, Inc. Antibody-sn-38 immunoconjugates with a cl2a linker
CN107753954A (zh) 2012-12-13 2018-03-06 免疫医疗公司 功效改进且毒性降低的抗体与sn‑38的免疫缀合物的剂量
CA2900955A1 (en) * 2013-03-14 2014-10-02 Oncomed Pharmaceuticals, Inc. Met-binding agents and uses thereof
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
CA2938819A1 (en) 2014-02-06 2015-08-13 Medicinal Chemistry Pharmaceuticals, Co., Ltd. Antibody to mucin 4 (muc4) glycopeptide and uses thereof
JP6447933B2 (ja) 2014-02-21 2019-01-09 アイビーシー ファーマスーティカルズ，インコーポレイテッド Ｔｒｏｐ−２発現細胞に対する免疫応答を誘発することによる疾患治療
CA2935748A1 (en) 2014-02-25 2015-09-03 Immunomedics, Inc. Humanized rfb4 anti-cd22 antibody
EP3160504B1 (en) 2014-06-24 2020-09-16 Immunomedics, Inc. Anti-histone therapy for vascular necrosis in severe glomerulonephritis
AU2016252771B2 (en) 2015-04-22 2021-12-16 Immunomedics, Inc. Isolation, detection, diagnosis and/or characterization of circulating Trop-2-positive cancer cells
JP6980980B2 (ja) 2015-06-25 2021-12-15 イミューノメディクス、インコーポレイテッドImmunomedics, Inc. 抗ｈｌａ‐ｄｒまたは抗ｔｒｏｐ‐２抗体と微小管阻害剤、ｐａｒｐ阻害剤、ブルトンキナーゼ阻害剤またはホスホイノシチド３‐キナーゼ阻害剤との併用は癌の治療効果を有意に改善する
WO2022010797A2 (en) 2020-07-07 2022-01-13 Bionecure Therapeutics, Inc. Novel maytansinoids as adc payloads and their use for the treatment of cancer
WO2022239720A1 (ja) 2021-05-10 2022-11-17 公益財団法人川崎市産業振興財団 抗原への結合親和性を低減させた抗体
WO2023056240A2 (en) 2021-09-28 2023-04-06 Frontaim Biomedicines, Inc. Multiple formats of molecular complexes

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5776427A (en) * 1992-03-05 1998-07-07 Board Of Regents, The University Of Texas System Methods for targeting the vasculature of solid tumors
DE69534530T2 (de) * 1994-08-12 2006-07-06 Immunomedics, Inc. Für b-zell-lymphom und leukämiezellen spezifische immunkonjugate und humane antikörper
US6261537B1 (en) * 1996-10-28 2001-07-17 Nycomed Imaging As Diagnostic/therapeutic agents having microbubbles coupled to one or more vectors
US6306393B1 (en) * 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
US7138103B2 (en) * 1998-06-22 2006-11-21 Immunomedics, Inc. Use of bi-specific antibodies for pre-targeting diagnosis and therapy
US7405320B2 (en) * 1998-06-22 2008-07-29 Immunomedics, Inc. Therapeutic and diagnostic conjugates for use with multispecific antibodies
AU1728800A (en) * 1998-11-18 2000-06-05 Genentech Inc. Antibody variants with higher binding affinity compared to parent antibodies
US6342219B1 (en) * 1999-04-28 2002-01-29 Board Of Regents, The University Of Texas System Antibody compositions for selectively inhibiting VEGF
WO2002068471A2 (en) * 2000-12-21 2002-09-06 Bristol-Myers Squibb Company Nucleic acid molecules and polypeptides for a human cation channel polypeptide

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2445319C2 (ru) * 2005-11-24 2012-03-20 Ганимед Фармасьютикалз Аг Моноклональные антитела к клаудину-18 для лечения рака
RU2432399C2 (ru) * 2006-06-14 2011-10-27 Эл Джи Лайф Сайенсиз Лтд. Семейство генов (lbfl313), ассоциированных с злокачественным ростом поджелудочной железы
RU2571923C2 (ru) * 2007-05-29 2015-12-27 Ганимед Фармасьютикалз Аг Моноклональные антитела против клаудина-18 для лечения рака

Also Published As

Publication number Publication date
KR101228124B1 (ko) 2013-01-31
US7238786B2 (en) 2007-07-03
AU2003250367A1 (en) 2003-12-31
WO2003106497A1 (en) 2003-12-24
US20040057902A1 (en) 2004-03-25
EP1521775B1 (en) 2015-09-09
KR20050010055A (ko) 2005-01-26
JP2006507803A (ja) 2006-03-09
JP5110768B2 (ja) 2012-12-26
CA2489469A1 (en) 2003-12-24
EP1521775A1 (en) 2005-04-13
CA2489469C (en) 2016-03-22

Similar Documents

Publication Publication Date Title
RU2005100777A (ru) Моноклональное антитело рам4 и его применение для диагностики и лечения рака поджелудочной железы
JP5139626B2 (ja) モノクローナル抗体ｈＰＡＭ４
JP5037122B2 (ja) 抗ｃｄ７４免疫複合体および方法
JP5138867B2 (ja) α−フェトタンパク質Ｉｍｍｕ３１抗体および融合タンパク質ならびにその使用方法
JP2006507803A5 (https=)
JP2006516086A5 (https=)
US20140010759A1 (en) Tumor specific anitbodies and uses therefor
JP2006513695A5 (https=)
JP2009022273A (ja) 二重特異性抗体とともに使用される新規なペプチド型薬剤の製造および使用

Legal Events

Date Code Title Description
FA93 Acknowledgement of application withdrawn (no request for examination)

Effective date: 20060713